61638-01-5

Usage

Uses

Used in Hair Dye Industry:
4-Amino-3-methoxyphenol is used as a colorant ingredient in oxidative hair dyes for its ability to react with hydrogen peroxide, facilitating the desired color change in hair. This reaction is essential for achieving the final hair color, making it a popular choice in the formulation of hair dyes.
Used in Pharmaceutical Industry:
As an intermediate in the synthesis of various pharmaceuticals, 4-Amino-3-methoxyphenol plays a significant role in the development of drugs with diverse therapeutic applications. Its chemical structure allows for the creation of compounds with specific biological activities, contributing to the advancement of medicinal chemistry.
Used in Organic Compounds Synthesis:
4-Amino-3-methoxyphenol is utilized as a key intermediate in the synthesis of a range of organic compounds, including dyes and other specialty chemicals. Its unique functional groups enable it to participate in various chemical reactions, making it a versatile building block in organic chemistry.

InChI:InChI=1/C7H9NO2/c1-10-7-4-5(9)2-3-6(7)8/h2-4,9H,8H2,1H3

Upstream product

• 17302-49-7 methoxy-[1,4]benzoquinone-1-oxime 
• 91-23-6 2-Nitroanisole 
• 7664-93-9 sulfuric acid 
• 150-19-6 O-methylresorcine 
• 121-57-3 4-aminobenzene sulfonic acid 
• 394-41-2 3-fluoro-4-nitrophenol 
• 448-19-1 4-fluoro-2-methoxy-1-nitrobenzene 
• 446-36-6 5-fluoro-2-nitrophenol 
• 40529-22-4 3-methoxy-4-(phenylazo)phenol 
• 1246999-30-3 2-(4-hydroxy-2-methoxyphenylazo)benzoic acid 
• 16292-95-8 4-nitro-3-methoxyphenol 
• 864245-30-7 4-(benzyloxy)-2-methoxy-1-nitrobenzene 
• 106063-48-3 4-benzenesulfonic acid 

Downstream Products

• 18113-07-0 4-Chloro-3-methoxyphenol 
• 5307-06-2 N-(4-hydroxy-2-methoxyphenyl)acetamide 
• 126059-04-9 ethyl 2-butyryl-3-<(4-hydroxy-2-methoxyphenyl)amino>acrylate 
• 1010803-99-2 C₁₄H₁₅NO₄S 
• 1160825-78-4 4-(4-amino-3-methoxyphenoxy)-3-nitropyridin-2-ylamine 
• 1470111-40-0 C₃₇H₄₁NO₁₁S 
• 1243402-74-5 N-(4-hydroxy-2-methoxyphenyl)methanesulfonamide 
• 919278-29-8 2-methoxy-4-[(5-methyl-5H-pyrrolo[3,2-d]pyrimidin-4-yl)-oxy]aniline 
• 2735-04-8 2,4-Dimethoxyaniline 
• 101908-41-2 2-chloro-N-(2,4-dimethoxyphenyl)acetamide 
• 5653-22-5 acetic acid-(4-ethoxy-2-methoxy-anilide) 
• 127285-30-7 4-ethoxy-2-methoxyaniline 
• 23042-75-3 N-(2,4-dimethoxyphenyl)acetamide 

Relevant academic research and scientific papers

COMPOUNDS FOR INHIBITING TNIK AND MEDICAL USES THEREOF

The present disclosure provides the compound having inhibitory property against TNIK having a specific chemical structure or its pharmaceutically acceptable salt. The present disclosure also provides a composition comprising the compound or its pharmaceutically acceptable salt. The present disclosure also provides a medical use of the compound, its salt or the composition comprising the compound or its pharmaceutically acceptable salt for treating or preventing cancer. The present disclosure also provides a method of treatment or prevention of cancer comprising administering the compound, its salt or the composition comprising the compound or its salt to a subject in need of such treatment or prevention.

Supported polymer magnets with high catalytic performance in the green reduction of nitroaromatic compounds

Magnetic Fe3O4 nanoparticles (MNPs) were prepared by a simple co-precipitation method using molar ratios of Fe2+:Fe3+ = 1:2 in ammonia solution, and subsequently were modified with tetraethyl orthosilicate (TEOS

The carbonate analogues of 5′-halogenated resiniferatoxin as TRPV1 ligands

A series of carbonate analogues of 5′-halogenated RTX have been investigated in order to examine the effect of the carbonate group as a linker and the role of halogens in the reversal of activity from agonism to antagonism for rat and human TRPV1 heterologously expressed in Chinese hamster ovary cells. The carbonate analogues showed similar activities to the corresponding RTX derivatives in rat TRPV1 but lower potency in human TRPV1. 5-Halogenation converted the agonists to partial agonists or full antagonists and the extent of antagonism reflected the order of I > Br > Cl > F, with a somewhat greater extent of antagonism for the derivatives of the 4-amino RTX surrogates compared to the corresponding derivatives of RTX itself. The carbonate analogues of I-RTX (60) and 5-bromo-4-amino-RTX (66) were potent and full antagonists with Ki(ant) = 2.23 and 2.46 nM, respectively, for rat TRPV1, which were ca. 5-fold more potent than I-RTX (2) under our conditions. The conformational analysis of the I-RTX-carbonate (60) indicated that its bent conformation was similar to that of I-RTX, consistent with compound 60 and I-RTX showing comparable potent antagonism.

Optimization of the azobenzene scaffold for reductive cleavage by dithionite; development of an azobenzene cleavable linker for proteomic applications

In this paper we conducted an extensive reactivity study to determine the key structural features that favour the dithionite-triggered reductive cleavage of the azo-arene group. Our stepwise investigation allowed identification of a highly reactive azo-arene structure 25 bearing a carboxylic acid, at the ortho position of the electron-poor arene and an ortho-Oalkyl-resorcinol as the electron-rich arene. Based on this 2(2′-alkoxy-4′-hydroxyphenylazo) benzoic acid (HAZA) scaffold, the orthogonally protected difunctional azo-arene cleavable linker 26 was designed and synthesized. Selective linker deprotection and derivatization was performed by introducing an alkyne reactive group and a biotin affinity tag. This optimized azo-arene cleavable linker led to a total cleavage in less than 10 s with only 1 mM dithionite. Similar results were obtained in biological media.

Novel potent BRAF inhibitors: Toward 1 nM compounds through optimization of the central phenyl ring

BRAF, a serine/threonine specific protein kinase that is part of the MAPK pathway and acts as a downstream effector of RAS, is a potential therapeutic target in melanoma. We have developed a series of small-molecule BRAF inhibitors based on a 1H-imidazo[4,5-b]pyridine-2(3H)-one scaffold (ring A) as the hinge binding moiety and a number of substituted phenyl rings C that interact with the allosteric binding site. The introduction of various groups on the central phenyl ring B combined with appropriate A- and C-ring modifications afford very potent compounds that inhibit V600EBRAF kinase activity in vitro and oncogenic BRAF signaling in melanoma cells. Substitution on the central phenyl ring of a 3-fluoro, a naphthyl, or a 3-thiomethyl group improves activity to yield compounds with an IC50 of 1 nM for purified V 600EBRAF and nanomolar activity in cells.

Total syntheses of clausamines A-C and clausevatine D

The first total syntheses of clausamines A-C and clausevatine D are reported. The key step involves a Diels-Alder reaction between an imine quinone and cyclic diene, allowing for the subsequent construction of the carbazole core in a regiospecific manner. Stereochemistry of the natural products is also discussed.

Methods for dyeing keratinous fibers with compositions which contain aminoindole couplers, oxidation dye precursors, and oxidizing agents at acid pHs

A method for dyeing keratin fibers, wherein a composition is applied to said fibers which contains, in a suitable dyeing medium, at least one coupler having formula (I) STR1 wherein R1 is hydrogen or alkyl; R2 and R3 are hydrogen, alkyl, COOR', where R' is alkyl or hydrogen; R4 is hydrogen, hydroxyalkyl, alkyl, polyhydroxyalkyl or acetyl or aminoalkyl wherein the amine may be mono- or disubstituted by alkyl; Z1 and Z2 are hydrogen, alkyl, hydroxy, halogen, alkoxy or a salt thereof; at least one precursor of an oxidation hair dye; and at least one oxidizing agent, the pH of the composition applied to the fibers being less than 7.

Reversible inhibitors of the gastric (H+/K+)-ATPase. 4. Identification of an inhibitor with an intermediate duration of action

3-Acyl-4-(arylamino)quinolines were previously identified as gastric (H+/K+)-ATPase inhibitors, and clinical efficacy has been demonstrated for compound 3 (SK and F 96067). In the present study the further structure- activity relatio